Literature DB >> 23151657

Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells.

Dong Xu1, Xingxing He, Ying Chang, Chuanrui Xu, Xiang Jiang, Shuzhen Sun, Jusheng Lin.   

Abstract

microRNAs (miRNAs) are negative regulators of gene expression and can function as tumor suppressors or oncogenes. Several miRNAs are associated with the development of hepatocellular carcinoma (HCC). miR-96 has been closely associated with cell proliferation and clonogenicity. Upregulation of miR-96 has been observed in various types of cancer. However, the biological function of miR-96 in hepatocarcinogenesis remains largely unknown. In this study, we demonstrated that miR-96 was upregulated in HCC and inhibition of miR-96 significantly suppressed HCC cell proliferation and colony formation. The expression levels of forkhead box O1 (FOXO1) and forkhead box O3a (FOXO3a) were upregulated when miR-96 was inhibited in HCC cells and the inhibition of FOXO1 and FOXO3a promoted HCC cell proliferation and colony formation. Collectively, these data reveal an important contribution of miR-96 to hepatocarcinogenesis and suggest a role for FOXO1 and FOXO3a dysregulation in this process. Thus, the use of a synthetic inhibitor of miR-96 may be a promising approach for the treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23151657     DOI: 10.3892/or.2012.2138

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  41 in total

1.  MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.

Authors:  Hong-Ming Song; Yi Luo; Deng-Feng Li; Chuan-Kui Wei; Kai-Yao Hua; Jia-Lu Song; Hui Xu; Niraj Maskey; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 2.  Posttranscriptional regulation of FOXO expression: microRNAs and beyond.

Authors:  P Urbánek; L-O Klotz
Journal:  Br J Pharmacol       Date:  2016-05-02       Impact factor: 8.739

Review 3.  MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine.

Authors:  Iván Lyra-González; Laura E Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  World J Hepatol       Date:  2015-06-18

4.  MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells.

Authors:  Haizhou Guo; Qianping Li; Weihao Li; Tianliang Zheng; Song Zhao; Zhangsuo Liu
Journal:  Mol Cell Biochem       Date:  2014-01-29       Impact factor: 3.396

5.  Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Josiah Cox; Steven Weinman
Journal:  Hepat Oncol       Date:  2016-01-01

6.  Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

Authors:  Yueming Chen; Xueyan Dong; Daojun Yu; Xianjun Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.

Authors:  Jingyi Jiang; Zheng Liu; Chao Ge; Cong Chen; Fangyu Zhao; Hong Li; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

8.  MicroRNA-96 Regulates Apoptosis by Targeting PDCD4 in Human Glioma Cells.

Authors:  Qing-Qing Ma; Jian-Ting Huang; Yun-Gang Xiong; Xiao-Yan Yang; Ran Han; Wang-Wen Zhu
Journal:  Technol Cancer Res Treat       Date:  2016-07-07

Review 9.  FOXO1: Another avenue for treating digestive malignancy?

Authors:  Feiyu Shi; Tian Li; Zhi Liu; Kai Qu; Chengxin Shi; Yaguang Li; Qian Qin; Liang Cheng; Xin Jin; Tianyu Yu; Wencheng Di; Jianwen Que; Hongping Xia; Junjun She
Journal:  Semin Cancer Biol       Date:  2017-09-28       Impact factor: 15.707

10.  Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma.

Authors:  Shijie Qin; Jieyun Xu; Yunmeng Yi; Sizhu Jiang; Ping Jin; Xinyi Xia; Fei Ma
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.